Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review

November 2021 | 60 pages | ID: T8589C24903EN
GlobalData

Abstracts

Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Tiziana Life Sciences Plc (Tiziana), formerly Alexander David Investments Plc, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company's other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in London, the UK.

Tiziana Life Sciences Plc Key Recent Developments

Sep 24,2021: Tiziana Life Sciences Announces Interim Results for the Six Months Ended 30 June 2021
Sep 07,2021: Tiziana Life Sciences: Change of registered office
Sep 07,2021: Tiziana Life Sciences Announces Change of Registered Office
Sep 03,2021: Tiziana Life Sciences posting of scheme document and notice of meetings
Aug 20,2021: Tiziana Life Sciences files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Tiziana Life Sciences Plc - Key Facts
Tiziana Life Sciences Plc - Key Employees
Tiziana Life Sciences Plc - Key Employee Biographies
Tiziana Life Sciences Plc - Major Products and Services
Tiziana Life Sciences Plc - History
Tiziana Life Sciences Plc - Company Statement
Tiziana Life Sciences Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Tiziana Life Sciences Plc - Business Description
R&D Overview
Tiziana Life Sciences Plc - Corporate Strategy
Tiziana Life Sciences Plc - SWOT Analysis
SWOT Analysis - Overview
Tiziana Life Sciences Plc - Strengths
Tiziana Life Sciences Plc - Weaknesses
Tiziana Life Sciences Plc - Opportunities
Tiziana Life Sciences Plc - Threats
Tiziana Life Sciences Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Tiziana Life Sciences Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 24, 2021: Tiziana Life Sciences Announces Interim Results for the Six Months Ended 30 June 2021
Sep 07, 2021: Tiziana Life Sciences: Change of registered office
Sep 07, 2021: Tiziana Life Sciences Announces Change of Registered Office
Sep 03, 2021: Tiziana Life Sciences posting of scheme document and notice of meetings
Aug 20, 2021: Tiziana Life Sciences files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ
Jun 24, 2021: Tiziana, FHI Clinical partner for Phase II intranasal Covid-19 drug trial
Jun 21, 2021: Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
Jun 02, 2021: Tiziana Life Sciences Posting of Notice of Annual General Meeting
May 18, 2021: Tiziana Life Sciences: Final results for the year ended 31 December 2020
May 18, 2021: Tiziana Life Sciences Amended announce Final Results for the Year Ended 31 December 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Tiziana Life Sciences Plc, Key Facts
Tiziana Life Sciences Plc, Key Employees
Tiziana Life Sciences Plc, Key Employee Biographies
Tiziana Life Sciences Plc, Major Products and Services
Tiziana Life Sciences Plc, History
Tiziana Life Sciences Plc, Other Locations
Tiziana Life Sciences Plc, Subsidiaries
Tiziana Life Sciences Plc, Key Competitors
Tiziana Life Sciences Plc, Ratios based on current share price
Tiziana Life Sciences Plc, Annual Ratios
Tiziana Life Sciences Plc, Annual Ratios (Cont...1)
Tiziana Life Sciences Plc, Interim Ratios
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Tiziana Life Sciences Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Tiziana Life Sciences Plc, Performance Chart (2016 - 2020)
Tiziana Life Sciences Plc, Ratio Charts
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Tiziana Life Sciences Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021